Characterization of the Interferon Alpha Response Against HCV in Hepatoma Cells

  • Christoph Seeger
  • Qing Zhu
  • Ju-Tao Guo
Conference paper


More than 170 million people worldwide are persistently infected with hepatitis C virus (HCV) and an estimated 70% of them suffer from variable and severe liver disease. Combination therapy with interferon alpha (IFN-a) and the nucleoside analogue ribavirin leads to sustained recovery in 45-80% of treated patients. The basis for the observed resistance to IFN therapy is not known. The development of a tissue culture system permissive for HCV replication in Huh7 cells has provided a new tool to investigate the mechanism of antiviral therapies against HCV. As in vivo, HCV RNA amplification in Huh7 cells appears to be inhibited by the antiviral programs induced by IFN-a. In this study we sought to further validate this system and investigated whether HCV replication could interfere with the IFN response.


Huh7 Cell Interferon Sensitivity Determine Region Subgenomic Replicon Human Fibrosarcoma Cell Line HT1080 Respective Parental Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17–35.PubMedCrossRefGoogle Scholar
  2. 2.
    Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000;288:339–344.PubMedCrossRefGoogle Scholar
  3. 3.
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485–1492.PubMedCrossRefGoogle Scholar
  4. 4.
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–982.PubMedCrossRefGoogle Scholar
  5. 5.
    Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus lb. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995;96:224–230.PubMedCrossRefGoogle Scholar
  6. 6.
    Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus lb infection. N Engl J Med 1996;334:77–81.PubMedCrossRefGoogle Scholar
  7. 7.
    Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110–113.PubMedCrossRefGoogle Scholar
  8. 8.
    Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000;290:1972–1975.PubMedCrossRefGoogle Scholar
  9. 9.
    Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001;75:8516–8523.PubMedCrossRefGoogle Scholar
  10. 10.
    Beard MR, Abell G, Honda M, Carroll A, Gartland M, Clarke B, Suzuki K, et al. An infectious molecular clone of a Japanese genotype lb hepatitis C virus. Hepatology 1999;30:316–324.PubMedCrossRefGoogle Scholar
  11. 11.
    Pietschmann T, Lohmann V, Rutter G, Kurpanek K, Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 2001;75:1252–1264.PubMedCrossRefGoogle Scholar
  12. 12.
    Frese M, Pietschmann T, Moradpour D, Haller O, Bartenschlager R. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol 2001;82:723–733.PubMedGoogle Scholar

Copyright information

© Springer Japan 2004

Authors and Affiliations

  • Christoph Seeger
    • 1
  • Qing Zhu
    • 1
  • Ju-Tao Guo
    • 1
  1. 1.Institute for Cancer ResearchFox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations